We’ve detected that you are using an outdated browser. For Windows users, this site is best experienced using Google Chrome, Firefox, or Microsoft Edge
In addition to serotonin and dopamine, REXULTI has high binding affinity to norepinephrine receptors
Pharmacodynamic profile—binding affinities across neurotransmitter systems1,a
Serotonin, dopamine, and norepinephrine modulate each other’s activity2
The mechanism of action of brexpiprazole is unknown. However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors.
aThe binding affinity of brexpiprazole was determined in vitro in cells overexpressing human receptors and is expressed as an nM concentration with lower values representing higher affinity. High binding affinity Ki <1 nM.1
Ki, binding affinity; nM, nanomolar.
Access a digital brochure detailing the binding profile for REXULTI,
including the pharmacodynamic profile.